Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery

July 19, 2018 updated by: Pettinari Matteo, Université Catholique de Louvain
Single center randomized study to test whether a prophylactic tricuspid annuloplasty at the time of mitral valve procedure can improve clinical and echocardiographical outcomes.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The optimal management of functional tricuspid regurgitation (FTR) in the setting of mitral valve operations remains controversial. The current practice is both center- and surgeon-specific with guidelines based on non-randomized data. A prospective randomized trial was performed to evaluate the worth of less-than-severe FTR repair during mitral valve procedures.

A single center randomized study was designed to allocate patients with less-than-severe FTR undergoing mitral valve surgery to be prophylactically treated + tricuspid valve annuloplasty (TVP- or TVP+). These patients were analysed using longitudinal cardiopulmonary exercise capacity, echocardiographic follow-up, and cardiac magnetic resonance (CMR). The primary outcome was more than mild tricuspid regurgitation (TR) recurrence with vena contracta >3mm. Secondary outcomes were maximal oxygen uptake (VO2 max) and right ventricular (RV) dimension and function.

Study Type

Interventional

Enrollment (Actual)

106

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients undergoing mitral valve surgery with less than sever tricuspid insufficiency

Exclusion Criteria:

  • presence of pacemaker lead through the tricuspid valve
  • acute endocarditis
  • minimally invasive approach
  • Functional mitral valve insufficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Tricuspid annuloplasty
Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
Tricuspid annuloplasty
No Intervention: No Tricuspid annuloplasty
Control patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of more than mild tricuspid insufficiency
Time Frame: 5 year
5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
VO2 max
Time Frame: 1 year
Physical function capacity measured by VO2 max
1 year
Right ventricular function
Time Frame: 5 year
Right ventricle function at the follow up
5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2009

Primary Completion (Actual)

December 31, 2010

Study Completion (Actual)

January 1, 2017

Study Registration Dates

First Submitted

July 11, 2018

First Submitted That Met QC Criteria

July 19, 2018

First Posted (Actual)

July 27, 2018

Study Record Updates

Last Update Posted (Actual)

July 27, 2018

Last Update Submitted That Met QC Criteria

July 19, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • UCLSaint Luc

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tricuspid Valve Insufficiency

Clinical Trials on Tricuspid annuloplasty

3
Subscribe